Pediatric Patient With Generalized Pustular Psoriasis With MEFV Gene Variant: Successful Treatment With Adalimumab

ABSTRACT Pediatric generalized pustular psoriasis (GPP) is a rare, severe, and potentially life‐threatening variant of childhood psoriasis. Early‐onset GPP has a well‐known association with deficiency of the interleukin‐36 receptor antagonist (DITRA). We present a case of a pediatric patient diagnosed with GPP found to have a heterozygous variant in the Mediterranean fever gene ( MEFV ) that was successfully treated with adalimumab. MEFV variants are a newly identified genetic risk factor for GPP. Our case highlights the need for ongoing genomic studies for childhood autoinflammatory diseases and the call for evidence‐based management for these challenging cases.